Related references
Note: Only part of the references are listed.Novel bivalent BET inhibitor N2817 exhibits potent anticancer activity and inhibits TAF1
Qian Wu et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Bromodomains: A novel target for the anticancer therapy
Shivani Gokani et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Identification of 3,5-Dimethylisoxazole Derivatives as BRD4 Inhibitors for the Treatment of Colorectal Cancer
Yifei Yang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Bromodomains: a new target class for drug development
Andrea G. Cochran et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine
Chang-Qing Tian et al.
CELL DEATH & DISEASE (2019)
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors
Jianping Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
BET Proteins as Targets for Anticancer Treatment
Anastasios Stathis et al.
CANCER DISCOVERY (2018)
Spatially constrained tandem bromodomain inhibition bolsters sustained repression of BRD4 transcriptional activity for TNBC cell growth
Chunyan Ren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor
Keith F. McDaniel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Bromodomains: Structure, function and pharmacology of inhibition
Elena Ferri et al.
BIOCHEMICAL PHARMACOLOGY (2016)
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxylethy]-1,3-dimethyl-piperazin-2-one (AZD5153)
Robert H. Bradbury et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Potent and selective bivalent inhibitors of BET bromodomains
Michael J. Waring et al.
NATURE CHEMICAL BIOLOGY (2016)
Design and characterization of bivalent BET inhibitors
Minoru Tanaka et al.
NATURE CHEMICAL BIOLOGY (2016)
Targeting BET bromodomains for cancer treatment
Marie Jung et al.
EPIGENOMICS (2015)
The bromodomain: From epigenome reader to druggable target
Roberto Sanchez et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2014)
Bromodomains mediate an acetyl-histone encoded antisilencing function at heterochromatin boundaries
AG Ladurner et al.
MOLECULAR CELL (2003)
Share Paper
